|
JPH0328966Y2
(cg-RX-API-DMAC7.html)
|
1987-10-16 |
1991-06-20 |
|
|
|
EP0582595A1
(en)
|
1991-04-26 |
1994-02-16 |
Surface Active Limited |
Novel antibodies, and methods for their use
|
|
WO1994018221A1
(en)
|
1993-02-02 |
1994-08-18 |
The Scripps Research Institute |
Methods for producing polypeptide binding sites
|
|
US5981478A
(en)
|
1993-11-24 |
1999-11-09 |
La Jolla Cancer Research Foundation |
Integrin-binding peptides
|
|
JP4139508B2
(ja)
|
1998-02-19 |
2008-08-27 |
旭化成株式会社 |
ヒトデルター3
|
|
JP4332581B2
(ja)
|
1998-02-19 |
2009-09-16 |
旭化成株式会社 |
ヒトデルタ−3
|
|
US6344443B1
(en)
|
1998-07-08 |
2002-02-05 |
University Of South Florida |
Peptide antagonists of tumor necrosis factor alpha
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
AU2757500A
(en)
|
1999-02-10 |
2000-08-29 |
Human Genome Sciences, Inc. |
33 human secreted proteins
|
|
WO2001012664A2
(en)
|
1999-08-19 |
2001-02-22 |
Chiron Corporation |
Notch receptor ligands and uses thereof
|
|
US6436703B1
(en)
|
2000-03-31 |
2002-08-20 |
Hyseq, Inc. |
Nucleic acids and polypeptides
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
AU2001280471A1
(en)
|
2000-08-11 |
2002-02-25 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
|
ATE346866T1
(de)
|
2001-09-14 |
2006-12-15 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, tandem-fv- antikörper
|
|
CA2459219A1
(en)
|
2001-09-17 |
2003-03-27 |
Protein Design Labs, Inc. |
Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
|
|
CA2500687A1
(en)
|
2002-10-02 |
2004-04-15 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20040115204A1
(en)
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
JP4906094B2
(ja)
|
2004-01-16 |
2012-03-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
レセプターを活性化し得る融合ポリペプチド
|
|
US20050175619A1
(en)
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
CA2580796C
(en)
|
2004-09-24 |
2013-03-26 |
Amgen Inc. |
Modified fc molecules having peptides inserted in internal loop regions
|
|
EP1805320B1
(en)
|
2004-10-22 |
2014-09-03 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
CN101123983A
(zh)
|
2004-10-27 |
2008-02-13 |
米迪缪尼股份有限公司 |
特定修饰对相关抗原的亲和力来调节抗体的特异性
|
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
CA2596248A1
(en)
|
2005-01-31 |
2006-08-10 |
Vaxinnate Corporation |
Method to identify polypeptide toll-like receptor (tlr) ligands
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
US20070141066A1
(en)
|
2005-12-16 |
2007-06-21 |
Genentech, Inc. |
Method for Diagnosing, Prognosing and Treating Glioma
|
|
EP1973945A4
(en)
|
2006-01-16 |
2009-11-18 |
Compugen Ltd |
NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS
|
|
EP2007808A4
(en)
|
2006-04-14 |
2010-07-21 |
Trubion Pharmaceuticals Inc |
BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
|
|
JP2009537147A
(ja)
|
2006-05-15 |
2009-10-29 |
シー レーン バイオテクノロジーズ, エルエルシー |
インフルエンザウイルスに対する中和抗体
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
JP5378795B2
(ja)
|
2006-10-20 |
2013-12-25 |
中外製薬株式会社 |
抗hb−egf抗体を有効成分として含む医薬組成物
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
WO2008119567A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific cd3-epsilon binding domain
|
|
EP2158221B1
(en)
|
2007-06-21 |
2018-08-29 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
US8580927B2
(en)
|
2008-01-31 |
2013-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
|
US8557965B2
(en)
|
2008-04-07 |
2013-10-15 |
Ablynx N.V. |
Single variable domains against notch pathway members
|
|
AR073538A1
(es)
|
2008-09-03 |
2010-11-17 |
Genentech Inc |
Anticuerpos multiespecificos que se unen especificamente al receptor del factor de crecimiento epidermico humano 2 (her2) y al factor de crecimiento endotelial vascular (vegf)
|
|
US10407513B2
(en)
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
|
JP5734201B2
(ja)
|
2008-12-19 |
2015-06-17 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディ及びその使用
|
|
PL2530091T3
(pl)
|
2010-01-29 |
2018-08-31 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciało przeciwko dll3
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
US9127021B2
(en)
|
2010-04-09 |
2015-09-08 |
Enanta Pharmaceuticals, Inc. |
Hepatitis C virus inhibitors
|
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
CA2817015A1
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
|
TWI736437B
(zh)
|
2010-11-30 |
2021-08-11 |
日商中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
|
EP2663334A4
(en)
|
2011-01-10 |
2016-01-13 |
Univ Emory |
ANTIBODIES AGAINST INFLUENZA
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
WO2012162067A2
(en)
|
2011-05-21 |
2012-11-29 |
Macrogenics, Inc. |
Cd3-binding molecules capable of binding to human and non-human cd3
|
|
WO2013002362A1
(ja)
|
2011-06-30 |
2013-01-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
|
KR101870555B1
(ko)
|
2011-08-23 |
2018-06-22 |
로슈 글리카트 아게 |
T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
|
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
|
SI2766397T1
(sl)
|
2011-10-11 |
2018-09-28 |
F. Hoffmann-La Roche Ag |
Izboljšano sestavljanje bispecifičnih protiteles
|
|
JP6267644B2
(ja)
|
2011-10-20 |
2018-01-24 |
アメリカ合衆国 |
抗cd22キメラ抗原受容体
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
WO2013180200A1
(ja)
|
2012-05-30 |
2013-12-05 |
中外製薬株式会社 |
標的組織特異的抗原結合分子
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
CN105102618B
(zh)
|
2012-12-27 |
2018-04-17 |
中外制药株式会社 |
异源二聚化多肽
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
GB201302447D0
(en)
*
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
CA2929044A1
(en)
|
2013-11-11 |
2015-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
BR112016020065A2
(pt)
|
2014-03-12 |
2018-02-20 |
Novartis Ag |
sítios específicos para modificar anticorpos para fazer imunoconjugados
|
|
JPWO2015146438A1
(ja)
|
2014-03-26 |
2017-04-13 |
国立大学法人東北大学 |
ヒト上皮増殖因子受容体を標的とした二重特異性抗体
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
ES2980787T3
(es)
|
2014-07-31 |
2024-10-03 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
EP2982692A1
(en)
*
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP2017531620A
(ja)
|
2014-09-12 |
2017-10-26 |
ジェネンテック, インコーポレイテッド |
システイン操作抗体及びコンジュゲート
|
|
US11154615B2
(en)
|
2014-11-11 |
2021-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Library of antigen-binding molecules including modified antibody variable region
|
|
EP3305322A4
(en)
|
2015-06-05 |
2018-12-26 |
Chugai Seiyaku Kabushiki Kaisha |
Combined use of immune activators
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
コントースボディ−単鎖標的結合物質
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
JP7125400B2
(ja)
|
2016-12-19 |
2022-08-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
標的化4-1bb(cd137)アゴニストとの併用療法
|
|
KR102692708B1
(ko)
|
2016-12-20 |
2024-08-07 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
|
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
|
JP7357616B2
(ja)
|
2017-12-05 |
2023-10-06 |
中外製薬株式会社 |
Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
|
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
|
TWI848953B
(zh)
*
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
US12435137B2
(en)
|
2018-08-03 |
2025-10-07 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
JP2022501325A
(ja)
|
2018-09-28 |
2022-01-06 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
|
KR20210068079A
(ko)
|
2018-09-28 |
2021-06-08 |
추가이 세이야쿠 가부시키가이샤 |
Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자
|
|
JP7611820B2
(ja)
*
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Dll3シングルドメイン抗体およびその治療用組成物
|
|
JP7803856B2
(ja)
|
2020-02-05 |
2026-01-21 |
中外製薬株式会社 |
組換え抗原結合分子を製造するおよび/または濃縮するための方法
|
|
JP7736688B2
(ja)
|
2020-03-31 |
2025-09-09 |
中外製薬株式会社 |
多重特異性抗原結合分子を製造するための方法
|
|
CA3173587A1
(en)
|
2020-03-31 |
2021-10-07 |
Chugai Seiyaku Kabushiki-Kaisha |
Dll3-targeting multispecific antigen-binding molecules and uses thereof
|